Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-690.73K) by net assets ($482.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Drugs Made In America Acquisition II Corp. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Jianfeng Group Co Ltd
SHG:600668
|
0.022x |
|
Mah Sing Group Bhd
KLSE:8583
|
0.022x |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
N/A |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
0.056x |
|
Jiangsu Yueda Investment Co Ltd
SHG:600805
|
0.002x |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
0.057x |
|
Welspun Enterprises Limited
NSE:WELENT
|
-0.147x |
|
NTG Nordic Transport Group A/S
CO:NTG
|
0.047x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2024)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-116.72K | $-194.30K | 1.665x | -- |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.